共存RET/PTC与TERT启动子突变预测甲状腺癌不良预后但对RET和MEK靶向治疗有效
该研究汇总TCGA-THCA、MSK-MetTropism和MSK-IMPACT数据中669例甲状腺乳头状癌(PTC)患者,对163例BRAF/RAS野生型患者进行基因型-死亡率比较分析。结果显示RET/PTC与TERT启动子突变显著共存(共存指数2.040,95%CI 1.110-3.747,P=0.023);同时携带两种突变者死亡率50%(7/14),HR 9.019(95%CI 2.635-30.870)。机制上RET/PTC通过MAP激酶通路上调突变型TERT,靶向RET和MEK可抑制突变型TERT。
要点
- RET/PTC与TERT启动子突变共存指数2.040(95%CI 1.110-3.747,P=0.023)。
- 同时携带RET/PTC和TERT启动子突变者死亡率50%(7/14),HR 9.019(95%CI 2.635-30.870)。
- RET/PTC通过MAP激酶通路上调突变型TERT,靶向RET和MEK可抑制突变型TERT。
核心结论
- 共存RET/PTC和TERT启动子突变可识别高死亡率的PTC独特临床实体,为基于基因的预后判断及依据RET/PTC和TERT状态的RET和MEK潜在靶向治疗提供新启示。
研究设计与样本
- 从TCGA-THCA、MSK-MetTropism和MSK-IMPACT数据集中汇总669例具有完整临床随访和遗传数据的PTC患者,其中163例BRAF/RAS野生型患者(112例女性、47例男性、4例未知)纳入死亡率比较基因型队列分析,中位年龄(IQR)46.00(33.00-61.00)岁,中位随访时间(IQR)16.13(8.09-27.91)个月。
主要发现
- RET/PTC与TERT启动子突变间共存指数为2.040(95%CI 1.110-3.747,P=0.023)。
- 死亡率:不携带任一突变者5%(5/100),仅携带TERT启动子突变者11.1%(2/18),仅携带RET/PTC者0%(0/31),同时携带两种遗传改变者50%(7/14)。
- 对应风险比(95%CI):以不携带任一突变者为参照1,仅TERT启动子突变者2.469(0.405-14.022),仅RET/PTC者3.296e-09(0-inf),同时携带两种突变者9.019(2.635-30.870),校正患者种族、性别和年龄后基本不变。
- BRAF/RAS与TERT启动子突变观察到类似结果。
- 机制上RET/PTC利用MAP激酶通路上调突变型TERT而非野生型TERT,靶向RET和MEK可抑制突变型TERT而非野生型TERT。
临床怎么用
- 作者认为共存RET/PTC和TERT启动子突变可识别高死亡率的PTC独特临床实体,为基于基因的预后判断及依据RET/PTC和TERT状态的RET和MEK潜在靶向治疗提供新启示。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: The role of RET/PTC rearrangement in the clinical outcomes of papillary thyroid cancer (PTC) is controversial and remains to be clearly undefined. OBJECTIVE: This work aimed to investigate the role of coexisting RET/PTC rearrangement and TERT promoter mutation in the prognosis and therapeutic targeting in PTC. METHODS: A total of 669 PTC patients with complete clinical follow-up and genetic data were pooled from thyroid cancer data sets TCGA-THCA, MSK-MetTropism, and MSK-IMPACT, from whom 163 patients (112 women and 47 men, 4 unknown) with wild-type (WT) BRAF/RAS were identified, with a median age (interquartile range [IQR]) of 46.00 (33.00-61.00) years and a median follow-up time (IQR) of 16.13 (8.09-27.91) months for comparative genotype cohort analysis of mortality. RESULTS: There was a significant concurrence index between RET/PTC and TERT promoter mutations, being 2.040 (95% CI, 1.110-3.747; P = .023). Mortality occurred in 5 of 100 (5%) patients harboring neither mutation, 2 of 18 (11.1%) patients harboring a TERT promoter mutation alone, 0 of 31 (0%) patients harboring a RET/PTC alone, and 7 of 14 (50%) patients harboring both genetic alterations, corresponding to hazard ratios (95% CI) of 1 (reference), 2.469 (0.405-14.022), 3.296e-09 (0-inf), and 9.019 (2.635-30.870), respectively, which remained essentially unchanged after adjustment for patient race, sex, and age. Similar results were observed with BRAF/RAS and TERT promoter mutations. Mechanistically, RET/PTC used the MAP kinase pathway to upregulate the mutated TERT, but not the WT TERT, and, correspondingly, targeting RET and MEK could suppress mutated TERT but not the WT TERT. CONCLUSION: Coexisting RET/PTC and TERT promoter mutation identify PTC as a unique clinical entity with high mortality, providing new implications for genetic-based prognostication and potential therapeutic targeting of RET and MEK guided by RET/PTC and TERT status.
引用
- Zhang W, Lin S, Wang Z, et al. Coexisting RET/PTC and TERT Promoter Mutation Predict Poor Prognosis but Effective RET and MEK Targeting in Thyroid Cancer. J Clin Endocrinol Metab. 2024. PMID: 38735658. doi:10.1210/clinem/dgae327
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。